
Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe ...
Rezpegaldesleukin, an investigational first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, demonstrated statistically significant efficacy across primary and key secondary endpoints in a global phase 2b clinical trial of adults …